Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis
Open Access
- 29 June 2011
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (8) , 1252-1260
Abstract
Complement-mediated bactericidal activity has long been regarded as the serological correlate of protective immunity againstNeisseria meningitidis. This was affirmed in 2005 at a WHO-sponsored meningococcal serology standardization workshop. The assay currently employed by most laboratories involves determining surviving bacterial colony counts on agar as a readout which is labor-intensive, time-consuming, and not amendable to rapid data analysis for clinical trials. Consequently, there is an acute need to develop a sensitive, high-throughput bactericidal assay to enable a rapid and robust assessment of the effectiveness of vaccine candidates. To this end, we have developed an automated, kinetic assay based on the fluorescent respiration product of resazurin which reduces assay volume, shortens assay time, and facilitates automation of data analysis. We demonstrate proof of concept for applicability of this high-throughput system with multiple meningococcal strains and utilizing different lots of human complement. The assay is robust and highly reproducible. Titers obtained by the fluorescence readout method are strongly correlated with the data obtained using the conventional, agar plate-based assay. These results demonstrate that the detection of bacteria that have survived the bactericidal reaction by measuring metabolic activity using a fluorescent dye as an alternative readout is a promising approach for the development of a high-throughput bactericidal assay.Keywords
This publication has 17 references indexed in Scilit:
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsHuman Vaccines, 2010
- Fast Tracking the Vaccine Licensure Process to Control an Epidemic of Serogroup B Meningococcal Disease in New ZealandClinical Infectious Diseases, 2009
- Meningococcal C conjugate vaccine: The experience in England and WalesVaccine, 2009
- Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit SeraInfection and Immunity, 2009
- A Robotic Platform for Quantitative High-Throughput ScreeningASSAY and Drug Development Technologies, 2008
- Neisseria meningitidis group B correlates of protection and assay standardization—International Meeting Report Emory University, Atlanta, Georgia, United States, 16–17 March 2005Vaccine, 2006
- Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle VaccineClinical and Vaccine Immunology, 2005
- Measurement of Serum Bactericidal Activity Specific forHaemophilus influenzaeType b by Using a Chromogenic and Fluorescent Metabolic IndicatorClinical and Vaccine Immunology, 2004
- Validation of colorimetric assay to detect complement-mediated antibody-dependent bactericidal activity against serogroups B and C Neisseria meningitidisBiologicals, 2003
- HUMAN IMMUNITY TO THE MENINGOCOCCUSJournal of Experimental Medicine, 1969